B. Riley Issues Pessimistic Outlook for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at B. Riley decreased their Q4 2025 EPS estimates for shares of Novavax in a research note issued on Monday, November 10th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($1.36) per share for the quarter, down from their previous estimate of ($0.83). B. Riley currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s FY2026 earnings at ($0.42) EPS.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to analyst estimates of $55.63 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. Novavax’s quarterly revenue was down 16.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald initiated coverage on Novavax in a research note on Friday, October 24th. They issued an “overweight” rating and a $18.00 price objective on the stock. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday. Bank of America reissued an “underperform” rating and set a $7.00 price objective (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. TD Cowen reduced their target price on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.38.

Novavax Stock Up 4.6%

Shares of NVAX opened at $7.44 on Wednesday. The company has a market capitalization of $1.21 billion, a P/E ratio of 3.26, a PEG ratio of 0.12 and a beta of 2.69. Novavax has a one year low of $5.01 and a one year high of $11.55. The business’s 50 day simple moving average is $8.38 and its 200-day simple moving average is $7.58. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34.

Institutional Investors Weigh In On Novavax

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC lifted its holdings in Novavax by 11.0% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 12,755 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,268 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Novavax by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock valued at $492,000 after acquiring an additional 1,718 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Novavax by 5.5% in the 2nd quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company’s stock valued at $215,000 after purchasing an additional 1,766 shares during the period. E Fund Management Co. Ltd. boosted its position in shares of Novavax by 9.0% in the 2nd quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 2,326 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after purchasing an additional 2,750 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.